[144] CHEMED CORP SEC Filing
CHE has a Form 144 notice indicating a planned sale of 2,000 common shares. The shares are to be sold through Raymond James & Associates on or about 11/24/2025 on the NYSE, with an aggregate market value of $876,000. Shares outstanding were 14,110,000; this is a baseline figure, not the amount being sold.
The seller acquired the shares through stock awards from the issuer in 2016. The filing also lists prior sales over the past three months by Kevin J McNamara, including 1,000 common shares for gross proceeds of $460,647 and 2,000 common shares for $922,794, both on 09/26/2025. The signer represents they are not aware of undisclosed material adverse information about the issuer.
- None.
- None.
FAQ
What does the CHE Form 144 filing disclose?
The Form 144 for CHE discloses a planned sale of 2,000 shares of the issuer's common stock, to be executed through Raymond James & Associates on or about 11/24/2025 on the NYSE, with an aggregate market value of $876,000.
How many CHE shares are planned to be sold under this Form 144?
The notice covers 2,000 common shares of CHE, with an indicated aggregate market value of $876,000 at the time of the filing.
How many CHE shares were outstanding in this Form 144 excerpt?
The Form 144 excerpt reports that the number of CHE common shares outstanding was 14,110,000, providing context for the planned sale amount.
Who is the selling security holder in the CHE Form 144 and how were the shares acquired?
The selling holder identified is Kevin J McNamara. The shares to be sold were acquired through stock awards from the issuer in 2016, with multiple award dates listed.
What prior CHE share sales are disclosed for the last 3 months?
The filing lists prior sales during the past three months by Kevin J McNamara: 1,000 common shares sold on 09/26/2025 for gross proceeds of $460,647 and 2,000 common shares sold the same day for $922,794.
What representation does the seller make in the CHE Form 144?
By signing the notice, the seller represents that they do not know of any material adverse information about the issuer's current or prospective operations that has not been publicly disclosed, and this representation also applies as of any stated Rule 10b5-1 plan adoption date.